Roche To Acquire Poseida Therapeutics In Deal Worth Up To $1.5B

Reuters (11/26, Graham, Burger) reports “Roche will acquire its U.S. collaboration partner Poseida Therapeutics in a cash deal worth up to $1.5 billion, banking on complex immune cell therapies against several types of blood cancer to boost its development pipeline.” According to Reuters, “Roche will pay $9 per share in cash and stockholders will also receive a non-tradeable contingent value right for up to $4 per share based on achievements, the companies said in a statement on Tuesday.” The deal, which is “expected to close in the first quarter of 2025,” will “add so-called allogeneic CAR-T cell therapies.”